Back to Search
Start Over
p62 at the crossroad of the ubiquitin-proteasome system and autophagy
- Source :
- Oncotarget
- Publication Year :
- 2016
- Publisher :
- Impact Journals, LLC, 2016.
-
Abstract
- The ubiquitin-proteasome system and autophagy are the two main proteolytic systems involved in, among other functions, the maintenance of cell integrity by eliminating misfolded and damaged proteins and organelles. Both systems remove their targets after their conjugation with ubiquitin. An interesting, yet incompletely understood problem relates to the fate of the components of the two systems. Here we provide evidence that amino acid starvation enhances polyubiquitination on specific sites of the proteasome, a modification essential for its targeting to the autophagic machinery. The uptake of the ubiquitinated proteasome is mediated by its interaction with the ubiquitin-associated domain of p62/SQSTM1, a process that also requires interaction with LC3. Importantly, deletion of the PB1 domain of p62, which is important for the targeting of ubiquitinated substrates to the proteasome, has no effect on stress-induced autophagy of this proteolytic machinery, suggesting that the domain of p62 that binds to the proteasome determines the function of p62 in either targeting substrates to the proteasome or targeting the proteasome to autophagy.
- Subjects :
- 0301 basic medicine
Proteasome Endopeptidase Complex
Protein degradation
03 medical and health sciences
Protein Domains
Ubiquitin
Stress, Physiological
Sequestosome-1 Protein
Autophagy
Humans
Animals
Amino Acids
Sequence Deletion
biology
Chemistry
p62
Editorial: Autophagy and Cell Death
Cell biology
proteasome
030104 developmental biology
PNAS Plus
Oncology
Proteasome
Proteolysis
protein degradation
biology.protein
Microtubule-Associated Proteins
HeLa Cells
Subjects
Details
- ISSN :
- 19492553
- Volume :
- 7
- Database :
- OpenAIRE
- Journal :
- Oncotarget
- Accession number :
- edsair.doi.dedup.....dcf842f277bd7462a2caa86457964499
- Full Text :
- https://doi.org/10.18632/oncotarget.13805